Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

By G. Simonneau, L. Rubin, N. Galiè, R. Barst, T. Fleming, A. Frost, P. Engel, M. Kramer, G. Burgess, Lorraine Collings and 3 more. Annals of Internal Medicine, 2008

596 citations recorded by the source corpus.

Subfields: Molecular Biology, Physiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/04e85a9e615d448965dbfa88e39db5e3fb1c8485

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. G. Simonneau
2. N. Galiè

Citations in the corpus

• Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. (2015, background): “Hospitalization for worsening pulmonary arterial hypertension 10 (4) 30 (12) 18 (14) 12 (10)”
• Pulmonary arterial hypertension (2013, background): “Indeed, there was a significant reduction in the number of patients showing clinical worsening and an improvement of survival among most severe patients [239].”